Advertisement
Some Investors May Be Willing To Look Past Huaren Pharmaceutical's (SZSE:300110) Soft Earnings
Investors were disappointed by Huaren Pharmaceutical Co., Ltd.'s (SZSE:300110 ) latest earnings release. We did some analysis, and found that there are some reasons to be cautious about the headline numbers.
See our latest analysis for Huaren Pharmaceutical
Our Take On Huaren Pharmaceutical's Profit Performance
Because of this, we think that it may be that Huaren Pharmaceutical's statutory profits are better than its underlying earnings power. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. You'd be interested to know, that we found 1 warning sign for Huaren Pharmaceutical and you'll want to know about this.
Our examination of Huaren Pharmaceutical has focussed on certain factors that can make its earnings look better than they are. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
Valuation is complex, but we're here to simplify it.
Discover if Huaren Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300110
Huaren Pharmaceutical
Produces and sells non-PVC soft bag infusions in China.
Good value with mediocre balance sheet.
Similar Companies
Market Insights
Advertisement
Weekly Picks
TA
Talos on Tesla ·
The "Physical AI" Monopoly – A New Industrial Revolution
Fair Value:US$665.3637.3% undervalued
25 followersusers have followed this narrative
14 commentsusers have commented on this narrative
17 likesusers have liked this narrative
MA
Marek_Trnka on CSG ·
Czechoslovak Group - is it really so hot?
Fair Value:€5547.0% undervalued
35 followersusers have followed this narrative
1 commentusers have commented on this narrative
13 likesusers have liked this narrative
AL
alex30free on Swedencare ·
The Compound Effect: From Acquisition to Integration
Fair Value:SEK 46.2846.5% undervalued
9 followersusers have followed this narrative
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
Recently Updated Narratives
RE
RecMag on Proximus ·
Proximus: The State-Backed Backup Plan with 7% Gross Yield and 15% Currency Upside.
Fair Value:€2567.1% undervalued
37 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
andre_santos on Spotify Technology ·
Spotify - A Fundamental and Historical Valuation
Fair Value:US$357.7624.6% overvalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
CO
Coward_Nutlick on Elicio Therapeutics ·
Very Bullish
Fair Value:US$10091.6% undervalued
12 followersusers have followed this narrative
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
Popular Narratives
DA
davidlsander on Ubisoft Entertainment ·
Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Fair Value:€33.887.8% undervalued
57 followersusers have followed this narrative
5 commentsusers have commented on this narrative
25 likesusers have liked this narrative
OO
OOO97 on Neo Performance Materials ·
Undervalued Key Player in Magnets/Rare Earth
Fair Value:CA$25.3319.7% undervalued
79 followersusers have followed this narrative
0 commentsusers have commented on this narrative
20 likesusers have liked this narrative
AN
AnalystConsensusTarget on NVIDIA ·
NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
Fair Value:US$253.0226.1% undervalued
1068 followersusers have followed this narrative
6 commentsusers have commented on this narrative
32 likesusers have liked this narrative
Trending Discussion
US
User on Tesla ·
When was the last time that Tesla delivered on its promises? Lets go through the list! The last successful would be the Tesla Model 3 which was 2019 with first deliveries 2017. Roadster not shipped. Tesla Cybertruck global roll out failed. They might have a bunch of prototypes (that are being controlled remotely) And you think they'll be able to ship something as complicated as a robot? It's a pure speculation buy.
3
|1
US
User on Tesla ·
This article completely disregards (ignores, forgets) how far China is in this field. If Tesla continues on this path, they will be fighting for their lives trying to sell $40000 dollar robots that can do less than a $10000 dollar one from China will do. Fair value of Tesla? It has always been a hype stock with a valuation completely unbased in reality. Your guess is as good as mine, but especially after the carbon credit scheme got canned, it is downwards of $150.
2
|0
TI
TickerTickle on Figma ·
Figma is still deeply embedded as the default design system in big companies, and the ecosystem (Buzz, Slides, Sites, Make) is clearly the strategic play rather than a one‑off product bet. None of those qualitative assumptions have really broken yet, the bigger change has been sentiment toward growth/AI software in general, not Figma’s product reality. Assuming ~30% annual growth, margins stepping up to 25%, and a 40x PE in 2030 with an 8.4% discount rate is too optimistic now considering how the broader market is now pricing similar SaaS names, which means you can believe in the long term thesis and still accept that the stock might chop sideways or even drift lower while expectations and multiples reset. I will be sharing an update soon.
1
|0